Details of the Drug Combination

General Information of Drug Combination (ID: DCXKIA6)

Drug Combination Name
Tocilizumab Azithromycin
Indication
Disease Entry Status REF
Coronavirus Disease 2019 (COVID-19) Phase 2 [1]
Component Drugs Tocilizumab   DM7J6OR Azithromycin   DMS6UOE
Monoclonal antibody Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tocilizumab
Disease Entry ICD 11 Status REF
Giant cell arteritis 4A44.2 Approved [2]
Rheumatoid arthritis FA20 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Juvenile idiopathic arthritis FA24 Phase 3 [3]
Castleman's disease 4B2Y Investigative [5]
Tocilizumab Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN interleukin-6 receptor (IL6R) TTDVAKP IL6RA_HUMAN; IL6RB_HUMAN Inhibitor [9]
Interleukin 6 receptor (IL6R) TT0E5SK IL6RA_HUMAN; IL6RB_HUMAN Modulator [10]
------------------------------------------------------------------------------------
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [6]
Bronchitis CA20 Approved [7]
Chancroid N.A. Approved [6]
Mycoplasma pneumoniae pneumonia N.A. Approved [6]
Staphylococcus aureus infection N.A. Approved [6]
Streptococcal pneumonia N.A. Approved [6]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [8]
Pneumonia caused by chlamydia N.A. Investigative [6]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Coronavirus Disease 2019 (COVID-19) DCV09V7 N. A. Phase 2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04347031) An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19. U.S. National Institutes of Health.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881).
4 ClinicalTrials.gov (NCT04320615) A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
5 Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020;98(3):131-137.
6 Azithromycin FDA Label
7 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
8 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
9 Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0.
10 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.